ImmuPharma Prepares To Report Lupuzor Study Results In April

23rd Mar 2018 11:17

LONDON (Alliance News) - Drug development company ImmuPharma PLC said on Friday it has been informed by Simbec-Orion that the data-base lock for the Lupuzor pivotal phase III trial study is expected on April 6, with results for the study expected in mid-April.

Lupuzor itself is ImmuPharma's lead programme for the treatment of Lupus, a life-threatening autoimmune disease.

"With the continued robust safety record of Lupuzor achieved over this trial, we look forward with confidence to reporting top line results in the near future," said Chairman Tim McCarthy.

Shares in ImmuPharma were down 3.1% at 123.50 pence on Friday.

---

Related Shares:

Immupharma